{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:58:08Z","timestamp":1777579088309,"version":"3.51.4"},"reference-count":110,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004897","name":"European Organisation for Research and Treatment of Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Oncology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/s1470-2045(18)30418-2","type":"journal-article","created":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T18:42:17Z","timestamp":1535654537000},"page":"e459-e469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review"],"prefix":"10.1016","volume":"19","author":[{"given":"Madeline","family":"Pe","sequence":"first","affiliation":[]},{"given":"Lien","family":"Dorme","sequence":"additional","affiliation":[]},{"given":"Corneel","family":"Coens","sequence":"additional","affiliation":[]},{"given":"Ethan","family":"Basch","sequence":"additional","affiliation":[]},{"given":"Melanie","family":"Calvert","sequence":"additional","affiliation":[]},{"given":"Alicyn","family":"Campbell","sequence":"additional","affiliation":[]},{"given":"Charles","family":"Cleeland","sequence":"additional","affiliation":[]},{"given":"Kim","family":"Cocks","sequence":"additional","affiliation":[]},{"given":"Laurence","family":"Collette","sequence":"additional","affiliation":[]},{"given":"Linda","family":"Dirven","sequence":"additional","affiliation":[]},{"given":"Amylou C","family":"Dueck","sequence":"additional","affiliation":[]},{"given":"Nancy","family":"Devlin","sequence":"additional","affiliation":[]},{"given":"Hans-Henning","family":"Flechtner","sequence":"additional","affiliation":[]},{"given":"Carolyn","family":"Gotay","sequence":"additional","affiliation":[]},{"given":"Ingolf","family":"Griebsch","sequence":"additional","affiliation":[]},{"given":"Mogens","family":"Groenvold","sequence":"additional","affiliation":[]},{"given":"Madeleine","family":"King","sequence":"additional","affiliation":[]},{"given":"Michael","family":"Koller","sequence":"additional","affiliation":[]},{"given":"Daniel C","family":"Malone","sequence":"additional","affiliation":[]},{"given":"Francesca","family":"Martinelli","sequence":"additional","affiliation":[]},{"given":"Sandra A","family":"Mitchell","sequence":"additional","affiliation":[]},{"given":"Jammbe Z","family":"Musoro","sequence":"additional","affiliation":[]},{"given":"Kathy","family":"Oliver","sequence":"additional","affiliation":[]},{"given":"Elisabeth","family":"Piault-Louis","sequence":"additional","affiliation":[]},{"given":"Martine","family":"Piccart","sequence":"additional","affiliation":[]},{"given":"Francisco L","family":"Pimentel","sequence":"additional","affiliation":[]},{"given":"Chantal","family":"Quinten","sequence":"additional","affiliation":[]},{"given":"Jaap C","family":"Reijneveld","sequence":"additional","affiliation":[]},{"given":"Jeff","family":"Sloan","sequence":"additional","affiliation":[]},{"given":"Galina","family":"Velikova","sequence":"additional","affiliation":[]},{"given":"Andrew","family":"Bottomley","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S1470-2045(18)30418-2_bib1","series-title":"Crossing the quality chasm: a new health system for the 21st century","year":"2001"},{"key":"10.1016\/S1470-2045(18)30418-2_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cct.2015.04.004","article-title":"Inclusion of patient-reported outcome measures in registered clinical trials: evidence from ClinicalTrials.gov (2007\u20132013)","volume":"43","author":"Vodicka","year":"2015","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/S1470-2045(18)30418-2_bib5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1634\/theoncologist.7-2-120","article-title":"The cancer patient and quality of life","volume":"7","author":"Bottomley","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/S1470-2045(18)30418-2_bib6","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrclinonc.2017.153","article-title":"Patient-reported outcomes in cancer care\u2014hearing the patient voice at greater volume","volume":"14","author":"LeBlanc","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib7","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/cncr.28935","article-title":"Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies","volume":"121","author":"Field","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(18)30418-2_bib8","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1177\/0962280213476378","article-title":"Practical and statistical issues in missing data for longitudinal patient reported outcomes","volume":"23","author":"Bell","year":"2014","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/S1470-2045(18)30418-2_bib9","series-title":"Quality of life: assessment, analysis and interpretation of patient-reported outcomes","author":"Fayers","year":"2013"},{"key":"10.1016\/S1470-2045(18)30418-2_bib11","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S1470-2045(16)30510-1","article-title":"Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards","volume":"17","author":"Bottomley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib12","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/annonc\/mdu385","article-title":"ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)","volume":"25","author":"Cardoso","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib13","author":"Higgins"},{"key":"10.1016\/S1470-2045(18)30418-2_bib14","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/S1470-2045(18)30418-2_bib15","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1016\/S1470-2045(16)30099-7","article-title":"Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials","volume":"17","author":"Ghislain","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12885-016-2152-1","article-title":"Methodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: a critical review","volume":"16","author":"Fiteni","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/S1470-2045(18)30418-2_bib17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejca.2017.06.025","article-title":"A systematic review of the quality of statistical methods employed for analysing quality of life data in cancer randomised controlled trials","volume":"83","author":"Hamel","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/S1470-2045(18)30418-2_bib18","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1002\/cncr.28010","article-title":"Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial","volume":"119","author":"Burris","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(18)30418-2_bib19","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1185\/03007995.2013.836078","article-title":"Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy","volume":"29","author":"Campone","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/S1470-2045(18)30418-2_bib20","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/cncr.28465","article-title":"Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer","volume":"120","author":"Welslau","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(18)30418-2_bib21","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2012.44.9694","article-title":"Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"31","author":"Hurvitz","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib22","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s10549-010-1084-8","article-title":"Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w\/o capecitabine)","volume":"123","author":"Svensson","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/S1470-2045(18)30418-2_bib23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.clbc.2011.03.019","article-title":"A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer","volume":"11","author":"Brufsky","year":"2011","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/S1470-2045(18)30418-2_bib24","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1200\/JCO.2007.12.6557","article-title":"Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment","volume":"25","author":"Thomas","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib25","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/cncr.26213","article-title":"Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer","volume":"118","author":"Corey-Lisle","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(18)30418-2_bib26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1471-2407-11-75","article-title":"Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial","volume":"11","author":"Nuzzo","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/S1470-2045(18)30418-2_bib27","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1200\/JCO.2010.28.8415","article-title":"Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer","volume":"28","author":"Di Leo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib28","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1001\/jama.2009.1204","article-title":"Lower-dose (6 mg daily) versus high-dose (30 mg daily) oral estradiol therapy of hormone-receptor-positive, aromatase-inhibitor-resistant advanced breast cancer: a randomized phase 2 study","volume":"302","author":"Ellis","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/S1470-2045(18)30418-2_bib29","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10549-009-0310-8","article-title":"Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: Quality-of-life assessment","volume":"117","author":"Zhou","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/S1470-2045(18)30418-2_bib30","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1524-4741.2008.00567.x","article-title":"Clinical interpretation of quality-of-life outcomes: an investigation of data from the randomized trial of gemcitabine plus paclitaxel compared with paclitaxel alone for advanced breast cancer","volume":"14","author":"Hopwood","year":"2008","journal-title":"Breast J"},{"key":"10.1016\/S1470-2045(18)30418-2_bib31","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s11136-011-9999-z","article-title":"Evaluating health-related quality-of-life therapeutic effectiveness in a clinical trial with extensive nonignorable missing data and heterogeneous response: results from a phase III randomized trial of gemcitabine plus paclitaxel versus paclitaxel monothe","volume":"21","author":"Moinpour","year":"2012","journal-title":"Qual Life Res"},{"key":"10.1016\/S1470-2045(18)30418-2_bib32","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2007.13.5822","article-title":"Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT","volume":"26","author":"Chia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib33","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.2003.04.075","article-title":"Phase III study of N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic\/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group study","volume":"22","author":"Reyno","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib34","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10549-006-9257-1","article-title":"Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG Trial MA.19","volume":"100","author":"Liu","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/S1470-2045(18)30418-2_bib35","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.1200\/JCO.2005.02.027","article-title":"Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer","volume":"23","author":"Jones","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib36","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2003.05.135","article-title":"Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK Mult","volume":"21","author":"Therasse","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib37","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S1470-2045(05)70100-5","article-title":"Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial","volume":"6","author":"Bottomley","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib38","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/annonc\/mdh395","article-title":"Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group","volume":"15","author":"Fountzilas","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib39","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2002.10.057","article-title":"Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment","volume":"20","author":"Howell","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib40","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1200\/JCO.2002.10.058","article-title":"Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial","volume":"20","author":"Osborne","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib41","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1200\/JCO.2001.19.14.3357","article-title":"Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate","volume":"19","author":"Buzdar","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib42","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/cncr.20400","article-title":"Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results from the gruppo oncologico nord ovest randomized trial","volume":"101","author":"Conte","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(18)30418-2_bib43","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1200\/JCO.2004.08.157","article-title":"Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer","volume":"22","author":"Keller","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib44","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","article-title":"Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results","volume":"20","author":"O'Shaughnessy","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib45","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1093\/annonc\/mdt274","article-title":"Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer","volume":"24","author":"Cort\u00e9s","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib46","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s10549-013-2589-8","article-title":"Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group","volume":"139","author":"L\u00fcck","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/S1470-2045(18)30418-2_bib47","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1200\/JCO.2012.44.7912","article-title":"AVEREL: a randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for her2-positive locally recurrent\/metastatic breast cancer","volume":"31","author":"Gianni","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib48","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000329066","article-title":"Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer","volume":"80","author":"Bachelot","year":"2011","journal-title":"Oncology"},{"key":"10.1016\/S1470-2045(18)30418-2_bib49","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","article-title":"Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer","volume":"28","author":"Blackwell","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib50","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1093\/annonc\/mdr014","article-title":"Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer","volume":"22","author":"Wu","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib51","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.ejca.2010.12.018","article-title":"Weekly docetaxel in metastatic breast cancer patients: no superior benefits compared to three-weekly docetaxel","volume":"47","author":"Schr\u00f6der","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/S1470-2045(18)30418-2_bib52","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1634\/theoncologist.2010-0012","article-title":"Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib","volume":"15","author":"Sherrill","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/S1470-2045(18)30418-2_bib53","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1185\/03007991003590860","article-title":"Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer","volume":"26","author":"Sherrill","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/S1470-2045(18)30418-2_bib54","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1159\/000140453","article-title":"Weekly vinorelbine versus docetaxel for metastatic breast cancer after failing anthracycline treatment","volume":"31","author":"Meier","year":"2008","journal-title":"Onkologie"},{"key":"10.1016\/S1470-2045(18)30418-2_bib55","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10549-008-0047-9","article-title":"A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study","volume":"115","author":"Fountzilas","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/S1470-2045(18)30418-2_bib56","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/S1470-2045(18)30418-2_bib57","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s10549-011-1725-6","article-title":"Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100)","volume":"130","author":"Cella","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/S1470-2045(18)30418-2_bib58","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1200\/JCO.2007.11.8851","article-title":"Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16","volume":"26","author":"Crump","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib59","first-page":"433","article-title":"Quality of life in metastatic breast cancer patients under chemotherapy or supportive care: a single-institution comparative study","volume":"16","author":"Karamouzis","year":"2007","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/S1470-2045(18)30418-2_bib60","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10549-007-9651-3","article-title":"A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study","volume":"109","author":"Cassier","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/S1470-2045(18)30418-2_bib61","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/01.cad.0000175587.31940.19","article-title":"Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluo","volume":"16","author":"von Minckwitz","year":"2005","journal-title":"Anticancer Drugs"},{"key":"10.1016\/S1470-2045(18)30418-2_bib62","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib63","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1200\/JCO.2004.02.037","volume":"22","author":"Bottomley","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib64","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1200\/JCO.2004.08.048","article-title":"Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342","volume":"22","author":"Winer","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib65","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.2003.04.040","article-title":"Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial","volume":"21","author":"Nabholtz","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib66","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.2003.08.013","article-title":"Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193)","volume":"21","author":"Sledge","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib67","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1200\/JCO.2002.03.090","article-title":"Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer","volume":"20","author":"Osoba","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib68","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer","volume":"20","author":"Vogel","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib69","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3816\/CBC.2010.n.037","article-title":"Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials","volume":"10","author":"Rugo","year":"2010","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/S1470-2045(18)30418-2_bib70","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/annonc\/12.suppl_1.S57","article-title":"Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data","volume":"12","author":"Eiermann","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib71","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1200\/JCO.2007.15.8485","article-title":"Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer","volume":"27","author":"Chan","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib72","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/1471-2407-13-164","article-title":"Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments","volume":"13","author":"Del Mastro","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/S1470-2045(18)30418-2_bib73","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.2012.45.2490","article-title":"Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02","volume":"31","author":"Park","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib74","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10549-015-3450-z","article-title":"Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02)","volume":"152","author":"Park","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/S1470-2045(18)30418-2_bib75","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.2014.56.9590","article-title":"Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA.31","volume":"33","author":"Gelmon","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib76","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib77","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10549-015-3633-7","article-title":"Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial","volume":"154","author":"Cortes","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/S1470-2045(18)30418-2_bib78","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10637-009-9285-x","article-title":"Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer","volume":"28","author":"Park","year":"2010","journal-title":"Invest New Drugs"},{"key":"10.1016\/S1470-2045(18)30418-2_bib79","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ejca.2017.05.009","article-title":"Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: results of the randomised MetaspHer study","volume":"82","author":"Pivot","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/S1470-2045(18)30418-2_bib80","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","article-title":"Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study","volume":"35","author":"Perez","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib81","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11136-016-1388-1","article-title":"Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial","volume":"26","author":"Shiroiwa","year":"2017","journal-title":"Qual Life Res"},{"key":"10.1016\/S1470-2045(18)30418-2_bib82","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.clbc.2016.06.014","article-title":"Final results of the randomized phase II NorCap-CA223 trial comparing first-line all-oral versus taxane-based chemotherapy for HER2-negative metastatic breast cancer","volume":"17","author":"Cinieri","year":"2017","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/S1470-2045(18)30418-2_bib83","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1186\/s12885-016-2823-y","article-title":"SAKK 24\/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer\u2014a multicenter, randomized phase III trial","volume":"16","author":"Rochlitz","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/S1470-2045(18)30418-2_bib84","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib85","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1200\/JCO.2004.02.112","article-title":"Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial","volume":"22","author":"Howell","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib86","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S1470-2045(15)00411-8","article-title":"Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial","volume":"17","author":"Takashima","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib87","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10549-016-4075-6","article-title":"Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial","volume":"161","author":"Yamamoto","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/S1470-2045(18)30418-2_bib88","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/annonc\/mdw622","article-title":"Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22\/99","volume":"28","author":"Pagani","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib89","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10549-016-4033-3","article-title":"A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study","volume":"161","author":"Harbeck","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/S1470-2045(18)30418-2_bib90","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1093\/annonc\/mdw316","article-title":"Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent\/metastatic breast cancer","volume":"27","author":"Vrdoljak","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib91","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor\u2013positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/S1470-2045(18)30418-2_bib92","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/annonc\/mdw139","article-title":"Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial","volume":"27","author":"Harbeck","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib93","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1185\/03007995.2016.1157060","article-title":"Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment","volume":"32","author":"Bell","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/S1470-2045(18)30418-2_bib94","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s11136-010-9793-3","article-title":"Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers","volume":"20","author":"Brundage","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/S1470-2045(18)30418-2_bib95","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejca.2015.12.025","article-title":"Patient-reported outcomes in head and neck and thyroid cancer randomised controlled trials: a systematic review of completeness of reporting and impact on interpretation","volume":"56","author":"Mercieca-Bebber","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/S1470-2045(18)30418-2_bib96","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1093\/annonc\/mdv283","article-title":"Planning and reporting of quality-of-life outcomes in cancer trials","volume":"26","author":"Schandelmaier","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(18)30418-2_bib97","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1002\/cncr.29489","article-title":"Quality of patient-reported outcome reporting across cancer randomized controlled trials according to the CONSORT patient-reported outcome extension: a pooled analysis of 557 trials","volume":"121","author":"Efficace","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(18)30418-2_bib98","doi-asserted-by":"crossref","first-page":"e110229","DOI":"10.1371\/journal.pone.0110229","article-title":"Systematic evaluation of the patient-reported outcome (PRO) content of clinical trial protocols","volume":"9","author":"Kyte","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/S1470-2045(18)30418-2_bib99","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1007\/s11136-016-1339-x","article-title":"The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols","volume":"25","author":"Mercieca-Bebber","year":"2016","journal-title":"Qual Life Res"},{"key":"10.1016\/S1470-2045(18)30418-2_bib100","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/S1470-2045(18)30418-2_bib101","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s11136-012-0252-1","article-title":"Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards","volume":"22","author":"Brundage","year":"2013","journal-title":"Qual Life Res"},{"key":"10.1016\/S1470-2045(18)30418-2_bib102","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jama.2017.21903","article-title":"Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension","volume":"319","author":"Calvert","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/S1470-2045(18)30418-2_bib104","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4103\/2229-3485.159943","article-title":"Common pitfalls in statistical analysis: clinical versus statistical significance","volume":"6","author":"Ranganathan","year":"2015","journal-title":"Perspect Clin Res"},{"key":"10.1016\/S1470-2045(18)30418-2_bib105","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.ejca.2008.05.008","article-title":"Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials","volume":"44","author":"Cocks","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/S1470-2045(18)30418-2_bib106","series-title":"Design and analysis of quality of life studies in clinical trials","author":"Fairclough","year":"2002"},{"key":"10.1016\/S1470-2045(18)30418-2_bib107","doi-asserted-by":"crossref","first-page":"e7586","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/S1470-2045(18)30418-2_bib108","doi-asserted-by":"crossref","first-page":"e010938","DOI":"10.1136\/bmjopen-2015-010938","article-title":"Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review","volume":"6","author":"Mercieca-Bebber","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/S1470-2045(18)30418-2_bib109","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1745-6215-12-58","article-title":"Modified versus standard intention-to-treat reporting: are there differences in methodological quality, sponsorship, and findings in randomized trials? A cross-sectional study","volume":"12","author":"Montedori","year":"2011","journal-title":"Trials"},{"key":"10.1016\/S1470-2045(18)30418-2_bib110","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s11136-015-1206-1","article-title":"The current practice of handling and reporting missing outcome data in eight widely used PROMs in RCT publications: a review of the current literature","volume":"25","author":"Rombach","year":"2016","journal-title":"Qual Life Res"},{"key":"10.1016\/S1470-2045(18)30418-2_bib111","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/(SICI)1097-0258(19980315\/15)17:5\/7<667::AID-SIM813>3.0.CO;2-6","article-title":"Why are missing quality of life data a problem in clinical trials of cancer therapy?","volume":"17","author":"Fairclough","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/S1470-2045(18)30418-2_bib112","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1007\/s11136-016-1411-6","article-title":"Reporting and dealing with missing quality of life data in RCTs: has the picture changed in the last decade?","volume":"25","author":"Fielding","year":"2016","journal-title":"Qual Life Res"},{"key":"10.1016\/S1470-2045(18)30418-2_bib113","doi-asserted-by":"crossref","first-page":"d40","DOI":"10.1136\/bmj.d40","article-title":"Strategy for intention to treat analysis in randomised trials with missing outcome data","volume":"342","author":"White","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/S1470-2045(18)30418-2_bib114","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/bmj.38478.497164.F7","article-title":"Systematic review of publication bias in studies on publication bias","volume":"331","author":"Dubben","year":"2005","journal-title":"BMJ"}],"container-title":["The Lancet Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204518304182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204518304182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:23:02Z","timestamp":1761459782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204518304182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":110,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1470204518304182"],"URL":"https:\/\/doi.org\/10.1016\/s1470-2045(18)30418-2","relation":{},"ISSN":["1470-2045"],"issn-type":[{"value":"1470-2045","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review","name":"articletitle","label":"Article Title"},{"value":"The Lancet Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(18)30418-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}